Glaukos Expands Retinal Pipeline with Exclusive License for Tri-Specific Biologic RO-104

  • Glaukos has secured an exclusive license for RO-104, a tri-specific biologic targeting nAMD, DME, DR, and RVO.
  • The deal also grants Glaukos access to RevOpsis’ RevMod™ platform for up to four additional retinal biologic candidates.
  • RO-104 is designed to block VEGF-A, VEGF-C, and Ang-2, showing superior preclinical efficacy compared to existing anti-VEGF therapies.
  • Financial terms of the agreement were not disclosed.

Glaukos is deepening its focus on retinal diseases, a strategic shift from its historical emphasis on glaucoma and corneal disorders. The deal with RevOpsis positions Glaukos to compete in a rapidly evolving retinal therapeutics market, where multi-specific biologics are gaining traction as next-generation treatments. The move underscores the industry’s push toward more targeted and efficient therapies for chronic retinal conditions.

Clinical Validation
How RO-104’s tri-specific mechanism will perform in human trials compared to existing anti-VEGF treatments.
Pipeline Expansion
The pace at which Glaukos leverages the RevMod platform to develop additional retinal candidates.
Commercial Strategy
Whether Glaukos can successfully integrate and commercialize RO-104 alongside its existing retinal portfolio.